Correction to Lancet Diabetes Endocrinol 2019; 7: 515-27

No authors listed

Published Erratum

No authors listed. Lancet Diabetes Endocrinol. 2019 Sep.

. 2019 Sep;7(9):e21.

doi: 10.1016/S2213-8587(19)30246-3. Epub 2019 Jul 15.

No abstract available

Erratum for

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators. Mosenzon O, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189517 Clinical Trial.